User profiles for SHAHROKH F. SHARIAT
Shahrokh F. Shariat, MDDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna and … Verified email at meduniwien.ac.at Cited by 99047 |
Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration
BACKGROUND: The literature on upper tract urothelial carcinoma (UTUC) has been limited
to small, single center studies. A large series of patients treated with radical …
to small, single center studies. A large series of patients treated with radical …
European Association of Urology guidelines on non–muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)
…, J Palou, BWG van Rhijn, M Rouprêt, SF Shariat… - European urology, 2022 - Elsevier
Context The European Association of Urology (EAU) has released an updated version of
the guidelines on non–muscle-invasive bladder cancer (NMIBC). Objective To present the …
the guidelines on non–muscle-invasive bladder cancer (NMIBC). Objective To present the …
EAU guidelines on non–muscle-invasive urothelial carcinoma of the bladder: update 2016
…, J Palou, M Rouprêt, BWG van Rhijn, SF Shariat… - European urology, 2017 - Elsevier
Context The European Association of Urology (EAU) panel on Non–muscle-invasive
Bladder Cancer (NMIBC) released an updated version of the guidelines on Non–muscle-invasive …
Bladder Cancer (NMIBC) released an updated version of the guidelines on Non–muscle-invasive …
EAU guidelines on non–muscle-invasive urothelial carcinoma of the bladder: update 2013
M Babjuk, M Burger, R Zigeuner, SF Shariat… - European urology, 2013 - Elsevier
… Shahrokh F. Shariat is a company consultant for Ferring Pharmaceuticals and participates
in trials for Alere Inc. on NMP22. He is the inventor or co-inventor of the following patents: …
in trials for Alere Inc. on NMP22. He is the inventor or co-inventor of the following patents: …
European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2020 update
…, RJ Sylvester, BWG Van Rhijn, R Zigeuner, SF Shariat - European urology, 2021 - Elsevier
… Burger d , Otakar Capoun e , Daniel Cohen f , Eva M. Compérat g , Nigel C. Cowan h , Jose
L. … Sylvester n , Bas WG van Rhijn d o , Richard Zigeuner p , Shahrokh F. Shariat b q r s t …
L. … Sylvester n , Bas WG van Rhijn d o , Richard Zigeuner p , Shahrokh F. Shariat b q r s t …
European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)-2019 update
…, J Palou, BWG van Rhijn, M Rouprêt, SF Shariat… - European urology, 2019 - Elsevier
… Shariat a b j k l , Richard Sylvester m , Richard Zigeuner n , Otakar Capoun o † , Daniel
Cohen p † , José Luis Dominguez Escrig q † , Virginia Hernández r † , Benoit Peyronnet s † , …
Cohen p † , José Luis Dominguez Escrig q † , Virginia Hernández r † , Benoit Peyronnet s † , …
[HTML][HTML] Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma
…, Y Tomita, A Bamias, T Lebret, SF Shariat… - … England Journal of …, 2021 - Mass Medical Soc
Background The role of adjuvant treatment in high-risk muscle-invasive urothelial
carcinoma after radical surgery is not clear. Methods In a phase 3, multicenter, double-blind, …
carcinoma after radical surgery is not clear. Methods In a phase 3, multicenter, double-blind, …
Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium
SF Shariat, PI Karakiewicz, GS Palapattu… - The Journal of …, 2006 - auajournals.org
Purpose : We present the characteristics and outcomes of a large, contemporary, consecutive
series of patients treated with radical cystectomy and pelvic lymphadenectomy for …
series of patients treated with radical cystectomy and pelvic lymphadenectomy for …
European association of urology guidelines on upper urinary tract urothelial carcinoma: 2017 update
…, BWG Van Rhijn, AH Mostafid, J Palou, SF Shariat - European urology, 2018 - Elsevier
… Shahrokh Shariat owns or co-owns the following patents: Shariat S, Slawin K. Methods to
determine prognosis after therapy for prostate cancer. US patent 60/266,976. …
determine prognosis after therapy for prostate cancer. US patent 60/266,976. …
Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy
ContextSalvage radiotherapy may potentially cure patients with disease recurrence after
radical prostatectomy, but previous evidence has suggested that it is ineffective in patients at …
radical prostatectomy, but previous evidence has suggested that it is ineffective in patients at …